Literature DB >> 14693837

Analysis of cell cycle regulator proteins in non-small cell lung cancer.

V Esposito1, A Baldi, G Tonini, B Vincenzi, M Santini, V Ambrogi, T C Mineo, P Persichetti, G Liuzzi, V Montesarchio, E Wolner, F Baldi, A M Groeger.   

Abstract

BACKGROUND/AIMS: Abnormalities of the proteins involved in cell cycle checkpoints are extremely common among almost all neoplasms. This study aimed to investigate the expression of four components of the cell cycle machinery-p21, p16, p53, and proliferating cell nuclear antigen (PCNA)-in non-small cell lung cancer (NSCLC).
METHODS: The expression of p21, p16, p53, and PCNA was examined in 68 well characterised NSCLC specimens using immunohistochemistry. The coregulation of these proteins and their influence on survival were analysed using both univariate and multivariate analyses.
RESULTS: By univariate analysis, the expression of all the proteins examined, except for PCNA, was significantly correlated with survival. In multivariate analysis, the only immunohistochemical parameter able to influence overall survival was p16, confirming the hypothesis that the RB-p16 tumour suppressor pathway is inactivated in most lung cancer samples. Finally, the group of patients with NSCLC who were negative for both p21 and p16 had a significantly shorter overall survival.
CONCLUSIONS: These results suggest that loss of control of cell cycle checkpoints is a common occurrence in lung cancers, and support the idea that functional cooperation between different cell cycle inhibitor proteins constitutes another level of regulation in cell growth control and tumour suppression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693837      PMCID: PMC1770176          DOI: 10.1136/jcp.57.1.58

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas.

Authors:  Y H Shim; G H Kang; J Y Ro
Journal:  Lab Invest       Date:  2000-05       Impact factor: 5.662

Review 2.  Molecular pathogenesis of lung cancer.

Authors:  Sabine Zochbauer-Muller; Adi F Gazdar; John D Minna
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

3.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

4.  Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.

Authors:  T Mitsudomi; N Hamajima; M Ogawa; T Takahashi
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

5.  Prognostic impact of p21/waf1/cip1 in colorectal cancer.

Authors:  T K Zirbes; S E Baldus; S P Moenig; S Nolden; D Kunze; S T Shafizadeh; P M Schneider; J Thiele; A H Hoelscher; H P Dienes
Journal:  Int J Cancer       Date:  2000-01-20       Impact factor: 7.396

6.  Recent trends in lung cancer mortality in the United States.

Authors:  A Jemal; K C Chu; R E Tarone
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

7.  Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.

Authors:  D S Franklin; V L Godfrey; D A O'Brien; C Deng; Y Xiong
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer.

Authors:  J X Zhou; G A Niehans; A Shar; J B Rubins; S P Frizelle; R A Kratzke
Journal:  Lung Cancer       Date:  2001-04       Impact factor: 5.705

9.  Clinical significance of p21 expression in non-small-cell lung cancer.

Authors:  Tsuyoshi Shoji; Fumihiro Tanaka; Tetsuya Takata; Kazuhiro Yanagihara; Yosuke Otake; Nobuharu Hanaoka; Ryo Miyahara; Tatsuo Nakagawa; Yozo Kawano; Shinya Ishikawa; Hiromichi Katakura; Hiromi Wada
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

Review 10.  RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer.

Authors:  Frederic J Kaye
Journal:  Oncogene       Date:  2002-10-07       Impact factor: 9.867

View more
  20 in total

1.  Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful?

Authors:  Jefree J Schulte; Jamie Steinmetz; Larissa V Furtado; Aliya N Husain; Mark W Lingen; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2020-04-29

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up.

Authors:  Ana María Gómez; Jose Ramón Jarabo Sarceda; Jose Antonio L García-Asenjo; Cristina Fernandez; Susana Hernandez; Julian Sanz; Elena Fernandez; Joaquin Calatayud; Antonio Torres; Florentino Hernando
Journal:  Tumour Biol       Date:  2014-01-19

4.  Mdig, a lung cancer-associated gene, regulates cell cycle progression through p27(KIP1).

Authors:  Dan Ma; Dan Guo; Wei Li; Hongwen Zhao
Journal:  Tumour Biol       Date:  2015-04-09

5.  Prognostic impact of S100A9 overexpression in non-small cell lung cancer.

Authors:  Hideki Kawai; Yoshihiro Minamiya; Naoko Takahashi
Journal:  Tumour Biol       Date:  2011-03-03

6.  Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer.

Authors:  V Esposito; A Baldi; A De Luca; G Tonini; B Vincenzi; D Santini; P Persichetti; A Mancini; G Citro; F Baldi; A M Groeger; M Caputi
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

Review 7.  Role of cell cycle regulators in lung carcinogenesis.

Authors:  Beatrice Eymin; Sylvie Gazzeri
Journal:  Cell Adh Migr       Date:  2010-01-16       Impact factor: 3.405

8.  Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.

Authors:  Samiha Mateen; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

9.  Synergistic cytotoxicity of ampelopsin sodium and carboplatin in human non-small cell lung cancer cell line SPC-A1 by G1 cell cycle arrested.

Authors:  Li Lu; Li-Ning Yang; Xue-Xi Wang; Chun-Li Song; Hong Qin; Yong-Jie Wu
Journal:  Chin J Integr Med       Date:  2016-06-14       Impact factor: 1.978

10.  Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients.

Authors:  Na-Hye Myong
Journal:  Cancer Res Treat       Date:  2008-06-30       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.